These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 38332160)

  • 21. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
    Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
    BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A risk model based on pyroptosis subtypes predicts tumor immune microenvironment and guides chemotherapy and immunotherapy in bladder cancer.
    Wu T; Li S; Yu C; Wu Y; Long H
    Sci Rep; 2022 Dec; 12(1):21467. PubMed ID: 36509838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic model development and molecular subtypes identification in bladder urothelial cancer by oxidative stress signatures.
    Dong Y; Wu X; Xu C; Hameed Y; Abdel-Maksoud MA; Almanaa TN; Kotob MH; Al-Qahtani WH; Mahmoud AM; Cho WC; Li C
    Aging (Albany NY); 2024 Feb; 16(3):2591-2616. PubMed ID: 38305808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identifying a Novel Defined Pyroptosis-Associated Long Noncoding RNA Signature Contributes to Predicting Prognosis and Tumor Microenvironment of Bladder Cancer.
    Lu H; Wu J; Liang L; Wang X; Cai H
    Front Immunol; 2022; 13():803355. PubMed ID: 35154117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification and validation of a dysregulated TME-related gene signature for predicting prognosis, and immunological properties in bladder cancer.
    Shen C; Chai W; Han J; Zhang Z; Liu X; Yang S; Wang Y; Wang D; Wan F; Fan Z; Hu H
    Front Immunol; 2023; 14():1213947. PubMed ID: 37965307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Uncovering the potential functions of lymph node metastasis-associated aberrant methylation differentially expressed genes and their association with the immune infiltration and prognosis in bladder urothelial carcinoma.
    Gao W; Zhang J; Tian T; Fu Z; Bai L; Yang Y; Wu Q; Wang W; Guo Y
    PeerJ; 2023; 11():e15284. PubMed ID: 37123010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.
    Chi M; Liu J; Mei C; Shi Y; Liu N; Jiang X; Liu C; Xue N; Hong H; Xie J; Sun X; Yin B; Meng X; Wang B
    J Exp Clin Cancer Res; 2022 May; 41(1):175. PubMed ID: 35581606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer.
    Tang R; Wang H; Liu J; Song L; Hou H; Liu M; Wang J; Wang J
    Eur J Med Res; 2024 Feb; 29(1):112. PubMed ID: 38336764
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel survival model based on a Ferroptosis-related gene signature for predicting overall survival in bladder cancer.
    Liang Y; Ye F; Xu C; Zou L; Hu Y; Hu J; Jiang H
    BMC Cancer; 2021 Aug; 21(1):943. PubMed ID: 34418989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of a propionate metabolism-related gene-based molecular subtypes and scoring system for predicting prognosis in bladder cancer.
    Zheng F; Wang Z; Li S; Xiong S; Yuan Y; Zeng J; Tan Y; Liu X; Xu S; Fu B
    Eur J Med Res; 2024 Jul; 29(1):393. PubMed ID: 39075554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unveiling Anoikis-related genes: A breakthrough in the prognosis of bladder cancer.
    Jiang S; Yang X; Lin Y; Liu Y; Tran LJ; Zhang J; Qiu C; Ye F; Sun Z
    J Gene Med; 2024 Jan; 26(1):e3651. PubMed ID: 38282152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prognostic model for bladder cancer based on cytoskeleton-related genes.
    Peng C; Guo S; Yang Z; Li X; Su Q; Mo W
    Medicine (Baltimore); 2023 Apr; 102(17):e33538. PubMed ID: 37115085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of a basement membrane-related genes signature with immune correlation in bladder urothelial carcinoma and verification in vitro.
    Li Y; Xu K; Zhang Y; Mao H; Qiu Q; Yan Z; Liu X; Du Y; Chen Z
    BMC Cancer; 2023 Oct; 23(1):1021. PubMed ID: 37872487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Generalized machine learning based on multi-omics data to profile the effect of ferroptosis pathway on prognosis and immunotherapy response in patients with bladder cancer.
    Liu X; Qiu Z; Zhang X; Su Z; Yi R; Zou D; Xie C; Jin N; Long W; Liu X
    Environ Toxicol; 2024 Feb; 39(2):680-694. PubMed ID: 37647346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of the prognostic value in lung adenocarcinoma based on anoikis-related genes and initial experimental validation.
    Guo W; Zhao G; Liu S; Deng T; Zhang G; Zhang B
    J Gene Med; 2023 Sep; 25(9):e3534. PubMed ID: 37259225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Novel TGF-β Risk Score Predicts the Clinical Outcomes and Tumour Microenvironment Phenotypes in Bladder Cancer.
    Liu Z; Qi T; Li X; Yao Y; Othmane B; Chen J; Zu X; Ou Z; Hu J
    Front Immunol; 2021; 12():791924. PubMed ID: 34975891
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in the tumor immune microenvironment of bladder cancer and establishes a prognostic model.
    Tan Z; Chen X; Zuo J; Fu S; Wang H; Wang J
    J Transl Med; 2023 Mar; 21(1):223. PubMed ID: 36973787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of the molecular subtypes and signatures to predict the prognosis, biological functions, and therapeutic response based on the anoikis-related genes in colorectal cancer.
    Zhai X; Chen B; Hu H; Deng Y; Chen Y; Hong Y; Ren X; Jiang C
    Cancer Med; 2024 May; 13(10):e7315. PubMed ID: 38785271
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deciphering the immunological and prognostic features of bladder cancer through platinum-resistance-related genes analysis and identifying potential therapeutic target P4HB.
    Xiong S; Li S; Zeng J; Nie J; Liu T; Liu X; Chen L; Fu B; Deng J; Xu S
    Front Immunol; 2023; 14():1253586. PubMed ID: 37790935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multi-cohort validation of Ascore: an anoikis-based prognostic signature for predicting disease progression and immunotherapy response in bladder cancer.
    Xie T; Peng S; Liu S; Zheng M; Diao W; Ding M; Fu Y; Guo H; Zhao W; Zhuang J
    Mol Cancer; 2024 Feb; 23(1):30. PubMed ID: 38341586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.